Keyword: Xolair

With blockbuster Xolair aging, Novartis is looking to usher in a successor to protect its sales. And it got one step closer this week.

Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost.

Roche and Novartis want to keep aging Xolair competitive for as long as possible, and they recently took a big step forward in doing that.

Xolair, Nucala, Cinqair, Fasenra and Dupixent will need to take a 50% to 68% discount off the list price to achieve cost-effectiveness, says ICER.

It hasn’t been an easy summer for AstraZeneca in the respiratory department, but the British drugmaker has finally come up with a win.

Roche’s Xolair has seen competitors encroach on its territory over the last few years. But now, it’s ready to carve out a new niche of its own.

GlaxoSmithKline is taking direct aim at severe asthma challenger Xolair from Novartis.

Roche managed 6% growth in the third quarter, but performance from key cancer meds highlighted biosimilar erosion ahead.

New meds are encroaching on a corner of the market for Novartis’ broader severe asthma treatment Xolair. But in response, the company is making it easier to diagnose the patient population it still has on lockdown.